Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

德诺苏马布 骨巨细胞瘤 兰克尔 间质细胞 医学 巨细胞 病理 巨细胞瘤 癌症研究 内科学 骨质疏松症 受体 激活剂(遗传学)
作者
Dan Branstetter,Scott D. Nelson,J. Carlos Manivel,Jean‐Yves Blay,Sant P. Chawla,David M. Thomas,Susie Jun,Ira Jacobs
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:18 (16): 4415-4424 被引量:359
标识
DOI:10.1158/1078-0432.ccr-12-0578
摘要

Abstract Purpose: Giant-cell tumor of bone (GCTB) is a locally aggressive, benign osteolytic tumor in which bone destruction is mediated by RANK ligand (RANKL). The RANKL inhibitor denosumab is being investigated for treatment of GCTB. We describe histologic analyses of GCTB tumor samples from a phase II study of denosumab in GCTB. Experimental Design: Adult patients with recurrent or unresectable GCTB received subcutaneous denosumab 120 mg every 4 weeks (with additional doses on days 8 and 15). The primary histologic efficacy endpoint was the proportion of patients who had a 90% or more elimination of giant cells from their tumor. Baseline and on-study specimens were also evaluated for overall tumor morphology and expression of RANK and RANKL. Results: Baseline tumor samples were typically composed of densely cellular proliferative RANKL-positive tumor stromal cells, RANK-positive rounded mononuclear cells, abundant RANK-positive tumor giant cells, and areas of scant de novo osteoid matrix and woven bone. In on-study samples from 20 of 20 patients (100%), a decrease of 90% or more in tumor giant cells and a reduction in tumor stromal cells were observed. In these analyses, thirteen patients (65%) had an increased proportion of dense fibro-osseous tissue and/or new woven bone, replacing areas of proliferative RANKL-positive stromal cells. Conclusions: Denosumab treatment of patients with GCTB significantly reduced or eliminated RANK-positive tumor giant cells. Denosumab also reduced the relative content of proliferative, densely cellular tumor stromal cells, replacing them with nonproliferative, differentiated, densely woven new bone. Denosumab continues to be studied as a potential treatment for GCTB. Clin Cancer Res; 18(16); 4415–24. ©2012 AACR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
Fly完成签到 ,获得积分10
2秒前
2秒前
3秒前
赫三问发布了新的文献求助10
4秒前
4秒前
YUAN完成签到,获得积分20
5秒前
5秒前
翊然甜周完成签到,获得积分10
5秒前
5秒前
5秒前
烟花应助yayahuan采纳,获得10
6秒前
mei发布了新的文献求助10
6秒前
AAAaa发布了新的文献求助10
7秒前
王王的苏完成签到,获得积分10
7秒前
彭于晏应助xin_qin_Wei采纳,获得10
8秒前
8秒前
研友_La17wL发布了新的文献求助10
8秒前
pjc完成签到,获得积分10
9秒前
张张完成签到,获得积分10
9秒前
汉堡包应助SharkLittle采纳,获得10
9秒前
Promise完成签到 ,获得积分10
9秒前
9秒前
Lorene完成签到,获得积分10
9秒前
夏硕完成签到,获得积分10
9秒前
zhaopen完成签到,获得积分20
11秒前
11秒前
11秒前
12秒前
17发布了新的文献求助10
12秒前
科研通AI6应助困了就睡采纳,获得10
13秒前
13秒前
太清完成签到 ,获得积分10
13秒前
14秒前
执着谷兰应助苦也采纳,获得10
14秒前
现代山雁完成签到 ,获得积分10
14秒前
14秒前
C胖胖完成签到,获得积分10
14秒前
星辰大海应助清脆千青采纳,获得10
15秒前
陈鑫发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
F-35B V2.0 How to build Kitty Hawk's F-35B Version 2.0 Model 2000
줄기세포 생물학 1000
The Netter Collection of Medical Illustrations: Digestive System, Volume 9, Part III - Liver, Biliary Tract, and Pancreas (3rd Edition) 600
Founding Fathers The Shaping of America 500
中国减肥产品行业市场发展现状及前景趋势与投资分析研究报告(2025-2030版) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 催化作用 遗传学 冶金 电极 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 4520654
求助须知:如何正确求助?哪些是违规求助? 3962893
关于积分的说明 12282759
捐赠科研通 3626324
什么是DOI,文献DOI怎么找? 1995683
邀请新用户注册赠送积分活动 1031853
科研通“疑难数据库(出版商)”最低求助积分说明 922215